DENVER, Colo. (247marketnews.com) — Lucid Diagnostics (NASDAQ:LUCD) cleared a major commercial hurdle for its EsoGuard esophageal precancer test: Medicare is now paying claims at an established rate of $1,938.01 per test. Coupled with a newly closed $15 million financing deal, the milestone gives the cancer-prevention diagnostics company fresh capital and a stronger platform to pursue commercial growth.
CEO and Chairman Lishan Aklog called the development a “seminal moment” for the company. Lucid says Medicare beneficiaries nationwide now have fully reimbursed access to the test, which is designed to detect esophageal precancer in at-risk patients, including people with chronic heartburn. The company collects esophageal cells using its EsoCheck device through a brief, noninvasive office procedure.
The financial implications could be significant if adoption follows. Medicare reimbursement removes a major obstacle for physicians and health systems considering the test and could strengthen Lucid’s case in negotiations with commercial insurers.
Lucid is also shoring up its finances. On October 21, 2026, it closed a $15 million private placement of Series C Convertible Preferred Stock with existing long-term shareholders, including holders of a majority of its senior secured convertible notes due 2029. The company plans to use the proceeds to accelerate commercial operations and fund working capital and general corporate needs.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.